Advancements in Previously Untreated Patients with DLBCL

T

POLARIX Trial Recap: Using Polatuzumab Vedotin for Previously Untreated DLBCL in the Community Setting

By Thomas Melchardt
85 views
June 28, 2024
0 Comments
Login to view comments. Click here to Login
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
20:25
SOHO Brazil 2024

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

Feat. A. Zelenetz
15:02
SOHO Brazil 2024

Summary of Updates in R/R DLBCL Treatment

Feat. A. Alencar
37:44
University of Colorado Division of Hematology

Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas

Feat. M. Kamdar
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
04:29
Juan Pablo Alderuccio

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

31:12
UChicago Medicine

Practice-Changing Abstracts in NHL and HL From ASH 2023

Feat. S. Smith
08:01
Georg Lenz

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
22:09
Scripps Health

New Updates in Frontline DLBCL

Feat. L. Nastoupil
15:29
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Current Standards of Care for Aggressive Lymphomas

Feat. U. Vitolo
09:32
SOHO 2023 Eleventh Annual Meeting

Upfront Management of DLBCL

Feat. C. Flowers
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
04:04
Wojciech Jurczak

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial